Want to see TENX full AI Analyst Report?
TENX Stock Chart & Stats
$2.32
-$0.11(-0.75%)
At close: 4:00 PM EDT
$2.32
-$0.11(-0.75%)
Day’s Range― - ―
52-Week Range$1.31 - $19.40
Previous CloseN/A
Volume1.16M
Average Volume (3M)9.37M
Market Cap
$71.11M
Enterprise Value$622.17
Total Cash (Recent Filing)$117.98M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta0.50
Next Earnings
Nov 18, 2026EPS Estimate
-0.36Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.49
Shares Outstanding37,423,916
10 Day Avg. Volume3,787,973
30 Day Avg. Volume9,371,527
Financial Highlights & Ratios
PEG Ratio-0.55
Price to Book (P/B)4.92
Price to Sales (P/S)0.00
P/FCF Ratio-13.35
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$9.63Price Target Upside314.87% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering10
EPS Forecast (FY)-1.45
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Debt-free Balance SheetEffectively zero debt limits refinancing pressure and preserves financial flexibility while Tenax advances its pipeline. The larger equity base provides a stronger capital foundation than in earlier years, although continued losses could erode that support over time.
Long-term Supply And Licensing StabilityThe Orion agreement secures a defined manufacturing and supply relationship for oral levosimendan through development and potential commercialization. Extended licensing flexibility also gives Tenax more time to pursue regulatory milestones without an immediately expiring approval timetable.
Potentially Differentiated Clinical SignalsAlthough the overall endpoint was not significant, consistent physiological and subgroup signals suggest TNX-103 may have greater utility in a more severely affected PH-HFpEF population. This could support a more focused registrational strategy and preserve the program’s clinical rationale.
Bears Say
Pre-revenue And Widening LossesTenax has no marketed-product revenue to offset substantial development spending, and losses have expanded materially across the reported periods. This weak earnings base limits internal funding capacity and leaves profitability dependent on successful clinical development and eventual commercialization.
Accelerating Cash BurnPersistent negative operating and free cash flow indicates that the business is not self-funding its pipeline. The sharper recent burn increases dependence on external capital or strategic transactions, potentially constraining development pace and increasing financing pressure.
Phase 3 Primary Endpoint FailureFailure on the primary endpoint materially raises regulatory and development risk for TNX-103, Tenax’s leading program. A narrower patient focus may help, but the company must still redesign or justify its registrational strategy, which can extend timelines and funding needs.
Tenax Therapeutics News
TENX FAQ
What was Tenax Therapeutics’s price range in the past 12 months?
Tenax Therapeutics lowest stock price was $1.31 and its highest was $19.40 in the past 12 months.
What is Tenax Therapeutics’s market cap?
Tenax Therapeutics’s market cap is $71.11M.
When is Tenax Therapeutics’s upcoming earnings report date?
Tenax Therapeutics’s upcoming earnings report date is Nov 18, 2026 which is in 58 days.
How were Tenax Therapeutics’s earnings last quarter?
Tenax Therapeutics released its earnings results on Jul 31, 2026. The company reported -$0.35 earnings per share for the quarter, beating the consensus estimate of -$0.381 by $0.031.
Is Tenax Therapeutics overvalued?
According to Wall Street analysts Tenax Therapeutics’s price is currently Undervalued.
Does Tenax Therapeutics pay dividends?
Tenax Therapeutics does not currently pay dividends.
What is Tenax Therapeutics’s EPS estimate?
Tenax Therapeutics’s EPS estimate is -0.36.
How many shares outstanding does Tenax Therapeutics have?
Tenax Therapeutics has 37,423,916 shares outstanding.
What happened to Tenax Therapeutics’s price movement after its last earnings report?
Tenax Therapeutics reported an EPS of -$0.35 in its last earnings report, beating expectations of -$0.381. Following the earnings report the stock price went down -9.272%.
Which hedge fund is a major shareholder of Tenax Therapeutics?
Currently, no hedge funds are holding shares in TENX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Tenax Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$9.63 (314.87% Upside)
$9.63 (314.87% Upside)
Blogger Sentiment
Neutral
TENX Sentiment 50%
Sector Average 63%
Sector Average 63%
Hedge Fund Trend
Increased
By 459.6K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $4.9M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days <0.1%
Last 30 Days ▲ 3.1%
Last 30 Days ▲ 3.1%
News Sentiment
Bullish
Bullish news 67%
Bearish news 33%
Bearish news 33%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-70.35%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
14.93%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Tenax Therapeutics
Tenax Therapeutics, Inc. is a specialized pharmaceutical enterprise dedicated to discovering, advancing, and bringing to market therapies for cardiovascular and pulmonary conditions throughout the United States and Canada. Its product pipeline features TNX-103 and TNX-102 (levosimendan), both of which have successfully completed Phase II clinical trials. These compounds are being developed to manage pulmonary hypertension, particularly that linked to heart failure with preserved ejection fraction (HFpEF), as well as other forms of associated pulmonary hypertension. Additionally, the company is progressing TNX-201 (imatinib), a tyrosine kinase inhibitor, designed to treat pulmonary arterial hypertension. Founded in 1967, the organization was initially known as Oxygen Biotherapeutics, Inc. until its rebranding to Tenax Therapeutics, Inc. in September 2014. The company maintains its corporate headquarters in Morrisville, North Carolina.
TENX Stock 12 Month Forecast
Average Price Target
$9.63
▲(314.87% Upside)
Technical Analysis
Enanta Pharmaceuticals
―
Arcturus Therapeutics
―
ProQR
―
Corbus Pharmaceuticals
―
Atea Pharmaceuticals
―
Ownership Overview
17.75% Insiders
8.54% Mutual Funds
35.91% Other Institutional Investors
30.01% Public Companies and
Individual Investors